Clinical predictors for nondiabetic kidney diseases in patients with type 2 diabetes mellitus: a retrospective study from 2017 to 2021

Yong-qin Zeng, Yu-xing Yang, Cheng-jing Guan, Zi-wei Guo, Bo Li, Hai-yan Yu, Rui-xue Chen, Ying-qian Tang and Rui Yan

Abstract

Background: Nondiabetic kidney disease (NDKD), which is prevalent among patients with diabetes mellitus (DM), is considerably different from diabetic kidney disease (DKD) in terms of the pathological features, treatment strategy and prognosis. Although renal biopsy is the current gold-standard diagnostic method, it cannot be routinely performed due to a range of risks. The aim of this study was to explore the predictors for differentiating NDKD from DKD to meet the urgent medical needs of patients who cannot afford kidney biopsy.

Methods: This is a retrospective study conducted by reviewing the medical records of patients with type 2 DM who underwent percutaneous renal biopsy at the Affiliated Hospital of Guizhou Medical University between January 2017 and May 2021. The demographic data, clinical data, blood test results, and pathological examination results of the patients were obtained from their medical records. Multivariate regression analysis was performed to evaluate the predictive factors for NDKD.

Results: A total of 244 patients were analyzed. The median age at biopsy was 55 (46, 62) years. Patients diagnosed with true DKD, those diagnosed with NDKD and those diagnosed with NDKD superimposed DKD represented 48.36% (118/244), 45.9% (112/244) and 5.74% (14/244), respectively, of the patient population. Immunoglobulin A nephropathy was the most common type of lesion in those with NDKD (59, 52.68%) and NDKD superimposed DKD (10, 71.43%). Independent predictive indicators for diagnosing NDKD included a DM duration of less than 5 years (odds ratio [OR] = 4.476; 95% confidence interval [CI]: 2.257–8.877; \( P < 0.001 \)), an absence of diabetic retinopathy (OR = 4.174; 95% CI: 2.049–8.502; \( P < 0.001 \)), a high RBC count (OR = 1.901; 95% CI: 1.251–2.889; \( P = 0.003 \)), and a negative of urinary glucose excretion test result (OR = 2.985; 95% CI: 1.474–6.044; \( P = 0.002 \)).

Conclusions: A DM duration less than 5 years, an absence of retinopathy, a high RBC count and an absence of urinary glucose excretion were independent indicators for the diagnosis of NDKD, suggesting that patients with NDKD may require a different treatment regimen than those with DKD.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Background**

The worldwide prevalence of diabetes mellitus (DM) has increased considerably in the past decades, mainly due to the increased prevalence of type 2 DM (T2DM) [1]. According to data published by the International Diabetes Federation, there are currently 463 million adults with DM (20–79 years) worldwide [2]. Meanwhile, the prevalence rates of macrovascular and microvascular complications associated with DM are also increasing dramatically [1]. Diabetic kidney disease (DKD), a common complication of DM driven by microvascular changes, is the leading cause of end-stage renal disease in developed countries and is a growing epidemic in China [3].

However, DKD is not the only form of kidney disease in patients with DM. Patients diagnosed with chronic kidney disease (CKD) and DM can have true DKD (CKD is a direct consequence of DM, and the histopathological patterns of the kidney are consistent with the changes from DKD, which are characterized by glomerular basement membrane thickening, mesangial matrix expansion, nodular glomerulosclerosis, and arteriolar hyalinosis), nondiabetic kidney disease (NDKD) (CKD caused by nondiabetic factors, such as immunoglobulin A nephropathy [IgA N] and membranous nephropathy [MN]), or a combination of both DKD and NDKD [4]. It has been previously reported that approximately 50% of patients with DM worldwide develop CKD but that only 20–75% of these patients with DM are diagnosed true DKD [5–7].

In clinical practice, the diagnosis of DKD relies predominantly on clinical presentations, including persistent proteinuria, hypertension, and a progressive decline in renal function[8]. Diagnostic kidney biopsy is rarely performed in patients with DM. Naturally, in the absence of a diagnostic biopsy, clinicians often diagnose patients with both DM and CKD as DKD, which inflates the true prevalence of DKD. However, there is considerable heterogeneity in the pathological features and prognoses between DKD and NDKD [4]. It is generally believed that some cases of NDKD are readily treatable or even alleviable, while cases of DKD are not. Therefore, establishing a correct diagnosis in patients with DM superimposed with CKD has decisive influence on the selection of treatment strategies, thus eventually affecting the renal prognosis.

Given that the diabetic environment can alter the progression of NDKD, the form of kidney disease in patients with DM can only be reliably distinguished by performing renal biopsy [9]. However, renal biopsy is an invasive procedure, and it has a range of limitations. First, most clinicians perform renal biopsy in only the patients with DM with indications of NDKD due to the trauma caused by renal biopsy [10]. Second, some patients with DM are unable to tolerate renal biopsy due to them having a poor physical condition. Third, it is difficult to perform renal biopsy at some non-specialist hospitals. Therefore, studies need to be performed to identify the diagnostic predictors for NDKD to meet medical needs for patients with DM who cannot afford kidney biopsy.

**Methods**

**Ethical approval**

Our study protocol was conducted in accordance with the Declaration of Helsinki guidelines. Given this is a retrospective cohort study, consent for conducting present study was not obtained, but written consent for renal biopsy was obtained from all of the included patients.

**Population and study design**

This study was retrospectively conducted by reviewing the medical records of patients with T2DM who underwent percutaneous renal biopsy at the Affiliated Hospital of Guizhou Medical University between January 2017 and May 2021, and the demographic data, clinical data, blood tests results, and pathological examination results were obtained. The diagnosis of T2DM at our institution complies with the criteria defined by American Diabetes Association [11]. CKD was defined as a decreased kidney function demonstrated by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² or markers of kidney damage (includingalbuminuria, urinary sediment abnormalities, electrolyte abnormalities or other abnormalities due to tubular disorders, histological abnormalities, structural abnormalities detected by imaging, and a history of a kidney transplantation), or both, for a duration of at least 3 months, regardless of the underlying cause [12]. The inclusion criteria were as follows: 1) Chinese ethnicity; 2) diagnosed with T2DM at the time of renal biopsy; 3) no previous renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, or kidney transplantation). The criteria for renal biopsy used in this study were uniform for all of the patient. we recommeded a renal biopsy pathological examination for a clear diagnosis after excluding contraindications for renal...
biopsy (i.e., uncorrectable bleeding tendency, severe hypertension, and active kidney infection) to all of the patients.

We first collected demographic information, including age, gender, body mass index (BMI), calculated by dividing the weight by the height squared, kg/m²), smoking status, drinking status, hypertension status (defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the use of antihypertensive medications)[13], dyslipidemia status (defined as cholesterol ≥ 5.2 mmol/L, triglycerides ≥ 1.7 mmol/L, low-density lipoprotein cholesterol ≥ 2.6 mmol/L, high-density lipoprotein cholesterol < 1.0 mmol/L in men and < 1.3 mmol/L in women, or the use of any lipid-lowering medication)[14], diabetic retinopathy status (DR) diagnosed by an ophthalmologist), DM duration, and hypertension duration (defined as the time from the first diagnosis to the time of the renal biopsy) to assess whether such parameters are associated with the renal pathological type.

Laboratory data, including the blood urea nitrogen level, creatinine level, estimated glomerular filtration rate (eGFR), uric acid level, random blood glucose level, hemoglobin A1c (HbA1c) level, red blood cell (RBC) count, hemoglobin (Hb) level, albumin (Alb) level, urinary glucose excretion, urinary protein level, urinary occult blood, and urinary protein excretion (UPE) obtained over 24 h; data from tumor marker analyses (CA199, CA153, CA125, alpha fetoprotein, carcinoembryonic antigen, etc.); and data from chest computed tomography, abdominal color doppler ultrasound, and other examinations, were collected. Approximately 9% of the patients accepted the detection of anti-phospholipase A2 receptor antibodies for diagnosing MN.

Finally, light microscopy, immunofluorescence, and electron microscopy were performed on all of the biopsy specimens, which were diagnosed by the same group of pathologists. Clinical pathology discussion was conducted by the same group of experienced nephrologists. The pathological diagnosis and classification of DKD were based on the pathological criteria published by the Renal Pathology Society in 2010 [15]. According to the pathological results of the renal biopsy, patients were classified into either the isolated DKD group, isolated NDKD group, or MIX group (NDKD superimposed on DKD).

Statistical analysis
For continuous variables, the data are presented as the median and interquartile range [median (25th percentile, 75th percentile)] for skewed data and as the mean ± standard deviation for normally distributed data. For categorical variables, the data are presented as the frequency (%). Analysis of variance or the Kruskal–Wallis test was used to compare continuous variables. The chi-square (χ²) test was used to assess the differences between the categorical variables. Univariate and multivariate logistic regression analyses were used to screen for the factors (including demographic information, such as gender, age, and BMI, and the covariates with a p-value of < 0.05 in univariate analysis) that were associated with the diagnosis of NDKD A two-sided p-value of < 0.05 was considered to indicate statistical significance. The statistical analysis was performed using SPSS software, version 26.0 (IBM Corp., Armonk, NY, USA).

Results
Characteristics of the study population
A total of 244 patients were analyzed, 66.66% of whom were male. The median age of the patients at the time of the renal biopsy was 55 (46, 62) years, the median DM duration was 5 (1, 10) years, the median HbA1c was 7% (6.13%, 8.1%), the median eGFR was 42.45 (21.46, 69.64) mL/min/1.73 m², and the median UPE was 3.69 (1.69, 5.89) g/24 h. The numbers of patients with hypertension, dyslipidemia, anemia and DR were 155 (63.52%), 213 (87.30%), 155 (63.52%), and 96 (39.34%), respectively. The patients were divided into three according to the type of renal pathology: the DKD (118, 48.36%), NDKD (112, 45.90%), and MIX (14, 5.74%) groups. The baseline clinical characteristics of the three groups are shown in Table 1. There was no significant difference in the age, gender, BMI, smoking and drinking statuses, hypertension duration, and dyslipidemia status of patients among three groups. The DM duration was the longest in the MIX group, followed by the DKD group. It was the shortest in the NDKD group. Compared with the patients in the DKD and MIX groups, the patients in the NDKD group had lower incidence rates of hypertension, DR, and urinary glucose and lower levels of UPE, but they had a higher eGFR, higher RBC count, higher Hb level, and higher urinary RBC count.

It is noteworthy that up to 87.29% of patients in the DKD group had class III or IV of diabetic nephropathy at the time of renal biopsy, while 100% of the patients in the MIX group had the same (Table 2). There were 14 pathological types in the NDKD group, including primary and secondary glomerular diseases. IgA N was the most common type of lesion, accounting for 52.68% (59/112) of all lesions in the patients with NDKD, and the second-most common type was MN, accounting for 18.75% (21/112) of all lesions in the patients with NDKD. The other 32 patients were diagnosed with other renal diseases (Table 3). Similar to the results in the NDKD group, IgA N (10, 71.43%) and MN (2, 14.29%) were the most
## Table 1  Baseline clinical and biochemical characteristics of the study population in the classification group

| Parameters                     | DKD Group (n = 118) | NDKD Group (n = 112) | MIX Group (n = 14) | P value |
|--------------------------------|---------------------|----------------------|-------------------|---------|
| Male, n(%)                     | 71.00 (60.17)       | 69.00 (61.61)        | 8.00 (57.14)      | 0.939   |
| Age, years, n(%)               | 54.50 (48.00, 61.00) | 54.50 (42.25, 62.00) | 61.50 (50.25, 65.00) | 0.251   |
| BMI, kg/m²                     | 25.06 ± 3.41        | 25.59 ± 4.55         | 24.53 ± 2.40      | 0.383   |
| Tobacco smoking, n(%)          | 0.471               |                      |                   |         |
| Yes                            | 47.00 (39.83)       | 37.00 (31.04)        | 4.00 (28.57)      |         |
| No                             | 71.00 (60.17)       | 75.00 (66.96)        | 10.00 (71.43)     |         |
| Alcohol drinking, n(%)         | 0.575               |                      |                   |         |
| Yes                            | 38.00 (32.20)       | 29.00 (25.89)        | 4.00 (28.57)      |         |
| No                             | 80.00 (67.80)       | 83.00 (74.11)        | 10.00 (71.43)     |         |
| Diabetes duration, years, n(%)  | < 0.001             |                      |                   |         |
| < 5                            | 28.00 (23.73)       | 74.00 (66.07)        | 3.00 (21.43)      |         |
| ≥ 5                            | 90.00 (76.27)       | 39.00 (34.83)        | 11.00 (78.57)     |         |
| DR, n(%)                       | < 0.001             |                      |                   |         |
| Yes                            | 67.00 (56.78)       | 23.00 (20.54)        | 6.00 (42.86)      |         |
| No                             | 51.00 (43.22)       | 89.00 (79.46)        | 8.00 (57.14)      |         |
| Hypertension, n(%)             | 0.008               |                      |                   |         |
| Yes                            | 87.00 (73.73)       | 62.00 (55.36)        | 11.00 (78.57)     |         |
| No                             | 31.00 (26.27)       | 50.00 (44.46)        | 3.00 (21.43)      |         |
| Hypertension duration, years, n(%) | 0.729              |                      |                   |         |
| < 5                            | 90.00 (76.27)       | 90.00 (80.36)        | 10.00 (71.43)     |         |
| ≥ 5                            | 28.00 (23.73)       | 22.00 (19.64)        | 4.00 (28.57)      |         |
| Dyslipidemia                   | 0.300               |                      |                   |         |
| Yes                            | 102.00 (86.44)      | 101.00 (90.18)       | 11.00 (78.57)     |         |
| No                             | 16.00 (13.56)       | 11.00 (9.82)         | 3.00 (21.43)      |         |
| Serum calcium, mg/dL           | 2.07 (1.97, 2.19)   | 2.15 (1.99, 2.28)    | 2.06 (1.97, 2.18) | 0.048   |
| BUN, mmol/L                    | 9.45 (6.80, 12.98)  | 8.10 (5.62, 12.21)   | 10.45 (7.88, 19.79) | 0.078   |
| Cr, μmol/L                     | 157.85 (112.03, 241.31) | 128.86 (112.03, 241.31) | 202.52 (169.32, 309.77) | 0.006   |
| eGFR, mL/min/1.73m²            | 37.98 (20.92, 58.49) | 52.86 (21.81, 78.98) | 23.56 (15.70,32.25) | 0.003   |
| Uric acid, μmol/L              | 391.85 (320.85, 456.88) | 421.30 (336.50, 510.13) | 376.90 (358.90, 445.28) | 0.134   |
| RBG, mmol/L                    | 9.50 (7.06, 12.68)  | 7.62 (5.93, 10.82)   | 11.05 (7.73, 13.74) | 0.029   |
| HbA1c, %                       | 7.13 (6.18, 8.96)   | 6.80 (6.10, 7.90)    | 6.87 (5.83, 7.90)  | 0.463   |
| RBC count, x 10¹²/L            | 3.67 (3.16, 4.21)   | 4.30 (3.79, 5.00)    | 3.33 (3.05, 3.77)  | < 0.001 |
| Hb, g/L                        | 107.00 (91.50, 125.00) | 125.00 (113.25, 147.75) | 96.00 (90.00, 113.25) | < 0.001 |
| Albumin, g/L                   | 32.92 (28.20, 38.50) | 34.10 (28.16, 43.32) | 31.89 (29.60, 39.30) | 0.325   |
| UPE, g/24 h, n(%)              | 0.006               |                      |                   |         |
| < 3.5                          | 48.00 (40.68)       | 62.00 (55.36)        | 6.00 (42.86)      |         |
| ≥ 3.5                          | 70.00 (59.32)       | 50.00 (44.64)        | 8.00 (57.14)      |         |
| Glucose in urine, n(%)         | < 0.001             |                      |                   |         |
| Positive                       | 62.00 (52.54)       | 30.00 (26.79)        | 6.00 (42.86)      |         |
| Negative                       | 56.00 (47.46)       | 82.00 (73.21)        | 8.00 (57.14)      |         |
| Occult blood in urine, n(%)    | 0.495               |                      |                   |         |
| Positive                       | 65.00 (55.08)       | 66.00 (58.93)        | 6.00 (42.86)      |         |
| Negative                       | 53.00 (44.92)       | 46.00 (41.07)        | 8.00 (57.14)      |         |
| RBC count in urine, count/HP   | 0.260               |                      |                   |         |
| 5.00 (2.00, 14.00)             | 6.00 (0.00, 33.00)  | 1.50 (0.00, 8.75)    |         |

The data were presented as median and interquartile range (median [25th percentile, 75th percentile]) and mean ± standard deviation for skewed data and normally distributed data, respectively; categorical data were presented as the frequency (%). Kruskal–Wallis test and the chi-square test were used to compare continuous variables and categorical variables, respectively. BMI: Body mass index, DR: Diabetic retinopathy, BUN: Blood urea nitrogen, Cr: Serum creatinine, eGFR: Estimated glomerular filtration rate, RBG: Random blood glucose, HbA1c: Hemoglobin A1c, RBC: Red blood cell, Hb: Hemoglobin, UPE: Urinary protein excretion.
common and second-most common types, respectively, in the MIX group.

Factors associated with the diagnosis of NDKD
Given the small number of patients in the MIX group which may imply a limited predictive value, we excluded these patients from further analysis. The univariate regression analysis identified a number of parameters that were significantly correlated with the diagnosis of NDKD, including the shorter DM duration (< 5 years) (odds ratio [OR] = 5.030; 95% confidence interval [CI]: 2.868–8.824; P < 0.001), absence of hypertension (OR = 2.263; 95% CI: 1.301–3.938; P = 0.004), absence of DR (OR = 5.084; 95% CI: 2.831–9.130; P < 0.001), eGFR (OR = 1.013; 95% CI: 1.005–1.022; P = 0.002), RBC count (OR = 2.494; 95% CI: 1.758–3.537; P < 0.001), Hb level (OR = 1.032; 95% CI: 1.019–1.044; P < 0.001), negative of urinary glucose (OR = 3.026; 95% CI: 1.741–5.259; P < 0.001), urinary RBC count (OR = 1.008; 95% CI: 1.002–1.014; P = 0.008), and reduced UPE level (< 3.5 g/24 h) (OR = 1.857; 95% CI: 1.096–3.145; P = 0.021). The demographic data, including gender, age, BMI, and variables that were observed to be statistically significant in the univariate analysis were used to further multivariate logistic regression analysis to identify the factors closely related to NDKD. The results demonstrated that four indicators were statistically significant in the diagnosis of NDKD: a diabetes duration of less than 5 years (OR = 4.476; 95% CI: 2.257–8.877; P < 0.001), absence of DR (OR = 4.174; 95% CI: 2.049–8.502; P < 0.001), the RBC count (OR = 1.901; 95% CI: 1.251–2.889; P = 0.003), and a negative test result for urinary glucose (OR = 2.985; 95% CI: 1.474–6.044; P = 0.002) (Table 4).

Table 2 The glomerular classification of diabetic kidney disease

| Class     | All (n = 244) | DKD Group (n = 118) | MIX Group (n = 14) |
|-----------|---------------|---------------------|--------------------|
| I         | 3 (1.23)      | 3 (2.54)            | 0                  |
| IIA       | 2 (0.82)      | 2 (1.69)            | 0                  |
| IIb       | 10 (4.10)     | 10 (8.48)           | 0                  |
| IIc       | 95 (38.93)    | 84 (71.19)          | 11 (78.57)         |
| IV        | 22 (9.02)     | 19 (16.10)          | 3 (21.43)          |

The data were presented as the frequency (%). NDKD, diabetic kidney disease; MIX Group, NDKD superimposed on DKD

Table 3 Pathological types in Non-diabetic kidney disease

| Type                        | All (n = 244) | NDKD Group (n = 112) | MIX Group (n = 14) |
|-----------------------------|---------------|----------------------|--------------------|
| IgA N, n(%)                 | 69 (28.28)    | 59 (52.68)           | 10 (71.43)         |
| MN, n(%)                    | 23 (9.43)     | 21 (18.75)           | 2 (14.29)          |
| MCD, n(%)                   | 6 (2.46)      | 6 (5.36)             | 0                  |
| MsPGN, n(%)                 | 5 (2.05)      | 5 (4.46)             | 0                  |
| Hypertensive nephropathy, n(%) | 5 (2.05)    | 4 (3.57)             | 1 (7.14)           |
| HSPN, n(%)                  | 5 (2.05)      | 5 (4.46)             | 0                  |
| PsG, n(%)                   | 3 (1.23)      | 3 (2.68)             | 0                  |
| Amyloid nephropathy, n(%)   | 4 (1.64)      | 3 (2.68)             | 1 (7.14)           |
| ANCA relative glomerulonephritis, n(%) | 4 (1.64) | 4 (3.57)             | 0                  |
| FSGS, n(%)                  | 3 (1.23)      | 3 (2.68)             | 0                  |
| LN, n(%)                    | 3 (1.23)      | 3 (2.68)             | 0                  |
| MPGN, n(%)                  | 1 (0.41)      | 1 (0.89)             | 0                  |
| C3G, n(%)                   | 1 (0.41)      | 1 (0.89)             | 0                  |
| OaG, n(%)                   | 1 (0.41)      | 1 (0.89)             | 0                  |

The data were presented as the frequency (%). NDKD, Non-diabetic kidney disease; MIX Group, NDKD superimposed DKD; IgA N, IgA nephropathy; MN, Membranous nephropathy; MCD, Minimal change disease; MsPGN, Mesangial proliferative glomerulonephritis; HSPN, Henoch-Schonlein purpura nephritis; PsG, Proliferative-sclerosing glomerulonephritis; FSGS, Focal segmental glomerulosclerosis; LN, Lupus nephritis; MPGN, Membranoproliferative glomerulonephritis; C3G, C3 glomerulopathy; OaG, Obesity-associated glomerulomegaly. Six patients were diagnosed as IgA N combined with MN, and one patients was diagnosed as MCD combined with hypertensive nephropathy.

Table 4 Multivariate regression analysis of factors related to the diagnosis of NDKD

| parameters                        | B    | OR   | 95% CI   | P value |
|-----------------------------------|------|------|----------|---------|
| Shorter Diabetes duration (< 5 years) | 1.499 | 4.476 | 2.257–8.877 | <0.001 |
| Absence of DR                     | 1.429 | 4.174 | 2.049–8.502 | <0.001 |
| RBC count                         | 0.643 | 1.901 | 1.251–2.889 | 0.003  |
| Negative of urinary glucose       | 1.094 | 2.985 | 1.474–6.044 | 0.002  |

DR, Diabetic retinopathy; RBC, Red blood cell
Discussion
With the widespread implementation of renal biopsy, NDKD is prevalent in the population of patients with DM [6, 16, 17]. It has been realized that not all patients with DM diagnosed with CKD develop renal dysfunction as a consequence of DM. Importantly, DKD and NDKD have considerably different treatment strategies and prognoses. Renal biopsy remains the only reliable way to distinguish the type of kidney disease in patients with DM. However, as an invasive procedure, renal biopsy has a range of limitations [10]. Therefore, there is an urgent need for clinicians to identify reliable predictors to be able to accurately distinguish diabetic patients with NDKD from DKD to meet the urgent medical needs of patients who cannot afford renal biopsy. In our study, 244 patients diagnosed with T2DM at the time of biopsy were analyzed to screen for the predictive factors of NDKD in patients with T2DM.

Some studies have investigated the prevalence of NDKD in cohorts of patients with DM and observed that the prevalence ranged from 18 to 62% [6, 17, 18]. In this study, 45.90% (112/244) of patients were diagnosed as isolated NDKD based on renal biopsy pathological results, which is a result that is consistent with previous studies. Furthermore, 5.74% (14/244) of patients were diagnosed as both DKD and NDKD. These results suggest that clinicians should pay more attention to the possibility of NDKD developing in patients with T2DM. Fourteen pathological types of NDKD were observed in the present study. For both the NDKD group and MIX group, IgA N was the most common type of lesion (52.68% and 71.43% in the NDKD group and MIX group, respectively), followed by MN (18.75% and 14.29% in the NDKD group and MIX group, respectively). This result is consistent with studies conducted Zhuo L, et al. [19, 20], but different with those of Liu D [21], which showed MN was the most common type of lesion in patients with DM. This difference may be caused by different renal biopsy criterion. We recommended that all patients with CKD superimposed on T2DM, undergo renal biopsy unless contraindications exist, whereas they mainly detected patients with nephrotic syndrome. For both the DKD group and MIX group, a high percentage of patients have reached class III or IV of diabetic nephropathy at the time of renal biopsy (87.20% and 100.00% in the NDKD group and MIX group, respectively), which maybe due to the lack of symptoms in early diabetic nephropathy then delayed the patients’ visit. Therefore, it is necessary to conduct regular urine tests and other screenings for kidney diseases in diabetic patients.

Further analysis showed that compared with DKD and MIX group, patients in the NDKD group had a lower incidence of hypertension, DR and urinary glucose, reduced UPE level, shorter DM duration, higher eGFR level, RBC count, Hb level and urinary RBC count. Multivariate logistic regression analysis showed that DM duration less than 5 years, absence of DR and higher RBC count were significant and independent predictive factors for diagnosis of NDKD. It is generally accepted that the risk of nephropathy increases with prolonged DM duration. Previous studies have proposed that DM duration is closely related to the prevalence of nephropathy in patients with T1DM [22]. Unlike T1DM, it is difficult to define the onset of T2DM accurately due to occult symptoms in the early stage of T2DM and lack of awareness and regular physical examination about this disease in most people. But several studies still showed that DM duration was shorter in diabetic patients with NDKD than DKD [5, 23], our results support this finding once again.

Both DR and DKD are common microvascular complication of T2DM. It is generally believed that the development of DR is often accompanied by that of DKD[24], so the patients without DR are more likely to have NDKD. Previous studies have shown that the incidence of DR in patients with NDKD ranged from 4.7%–14.9% [17, 18, 25, 26]. In the present study, the incidence of DR in the NDKD group was 20.54%, a bit higher than the previous data. The reason may be that we conducted ophthalmoscope examination for all patients with T2DM, thus avoiding the possibility of missing a diagnosis. Our data revealed that the absence of DR could be a factor for predicting NDKD in patients with T2DM, but it is not an exclusion criterion for DKD. Notably, a cohort study proposed that diabetic nephropathy was also an independent risk factor for the development and progression of DR [27]. In one word, our results reminds nephrologists again that routine ophthalmoscope examination should be performed on patients with T2DM to diagnose and treat early.

To our knowledge, the present study suggested that higher RBC count and negative of urinary glucose had predictive value for diagnosis of NDKD for the first time. Previous studies have explored the level of Hb not RBC count in patients with NDKD and DKD, and suggested that higher level of Hb is a predictive factor for NDKD [28, 29]. In our study, univariate regression analysis showed that both RBC count (OR = 2.494; 95% CI: 1.758–3.537; Ρ < 0.001) and Hb level (OR = 1.032; 95% CI: 1.019–1.044; Ρ < 0.001) are associated with NDKD, but after adjusting gender, age and BMI, et, multivariate logistic regression analysis showed that RBC count (OR: 1.901; 95% CI: 1.251–2.889; Ρ = 0.003) not Hb level has a predictive value for the diagnosis of NDKD. It makes sense, synthesizing erythropoietin (EPO) is one of the
key duty of kidney [30]. Renal anemia is common in CKD patients and also one of the most common complications of DKD, which mainly related to the deficiency of EPO [31]. A study reported that EPO-related anemia can occur early in patients with DKD, but usually does not occur in patients with NDKD of similar severity [32]. One possible underlying mechanism is that early lesions in patients with DKD mainly involve diffuse thickening of the glomerular basement membrane and mesangial matrix hyperplasia [15], which could greatly affect the synthesis of EPO, but NDKD does not. Given EPO is the major stimulator of RBC production [33], it is not surprising that RBC count is more predictive than Hb level. Furthermore, it is also the first time that urinary glucose was collected in predictive analysis for the diagnosis of NDKD. Although there was no significant difference of HbA1c level between patients with DKD and NDKD, patients in DKD groups had higher level of random blood glucose, which may contribute to positive of urinary glucose in patients with DKD. Other underlying pathogenesis requires further exploration.

As for other parameters, there is controversy of the clinical value of UPE between patients with DKD and NDKD [18, 34]. The results of the present study showed that the UPE level was higher in the DKD group versus the NDKD group, but it is not associated with the diagnosis of NDKD. These differences may be related to the criterion of renal biopsy and region, et. We also found that the eGFR in the NDKD group was higher than that in the DKD group, but it is not associated with the diagnosis of NDKD. As a chronic complication of DM, DKD has a slowly onset, the lack of obvious symptoms usually bring a long duration of disease and significant damage to kidney function. However, most patients with NDKD such as IgA N and MN with an acute onset are more likely to show obvious symptoms such as proteinuria and edema, thus can seek hospital visit early.

Although many studies have explored the differential diagnosis of DKD and NDKD, the results from these studies varied, thus differentiating NDKD from DKD effectively and based on scientific evidence remains under further exploration. A strength of this study is that we recommended to all of the patients to undergo renal biopsy unless there were contraindications for it, which minimizes the selection bias as much as possible. In addition, we included as many relevant parameters as possible. However, there are also some limitations to this study. This study is retrospective and was performed at a single center, so applying the results to populations in other countries and regions will produce results that need to be interpreted cautiously due to the restrictive patient population in this study; Moreover, it cannot be entirely ruled out that there were no unmeasured confounding factors that could have possibly influenced the observed association in this study.

**Conclusions**

Diabetic nephropathy is regarded as a major cause of end-stage renal disease, and true DKD usually requires treatment by glycemic control and dual sodium-dependent glucose transporters 2 (SGLT2) and rennin angiotensin system (RAS) inhibition. However, NDKD may require additional therapeutic approaches. The present study demonstrated that a DM duration of less than 5 years, the absence of retinopathy, an elevated of RBC count, and the absence of urinary glucose excretion are independent indicators associated with the diagnosis of NDKD, suggesting that patients with NDKD may require a different treatment regimen than those with DKD when kidney biopsy cannot be performed. Given this study was performed at a single center, the conclusions derived from this work should be further analyzed and validated at other centers in China.

**Abbreviations**

Alb: Albumin; BMI: Body mass index; BUN: Blood urea nitrogen; CI: Confidence interval; CKD: Chronic kidney disease; Cr: Creatinine; DR: Diabetic retinopathy; DM: Diabetes mellitus; DKD: Diabetic kidney disease; eGFR: Estimated glomerular filtration rate; EPO: Erythropoietin; Hb: Hemoglobin; HbA1C: Hemoglobin A1c; IgA N: IgA nephropathy; MN: Membrane nephropathy; NDKD: Non-diabetic kidney disease; OR: Odds ratio; RBC: Red blood cell; T2DM: Type 2 diabetes mellitus; UPE: Urinary protein excretion.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

Yong-qin Zeng, Yu-xing Yang, Zi-Wei Guo, Bo Li, Hai-yan Yu, Rui-xue Chen, Cheng-jing Guan, Ying-qian Tang collected demographic, clinical and laboratory data. Yong-qin Zeng contributed to conception and design of the study and analyzed and interpreted data. Yong-qin Zeng and Rui Yan contributed to writing and revising the manuscript. All authors reviewed the manuscript and approved the final version for publication.

**Funding**

This work was supported by the National Natural Science Foundation of China (81960140), Guizhou Provincial Natural Science Foundation (QK[2021]379), Project of Guizhou Provincial Administration of Traditional Chinese Medicine(QZYY-2021–020), Science Technology Foundation of Guizhou Provincial Health Commission (gzwjkj2020-1–002).

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not publicly available due to relevant data protection but are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The present study was in accordance with Declaration of Helsinki guidelines. Given the study was a retrospective study and the data used in this study was anonymized, the waiver of ethics approval and consent were given by The Ethics Committee of Affiliated Hospital of Guizhou Medical University.
Consent for publication  
Not applicable.

Competing interests  
We declare no competing interests.

Author details  
1 Department of Nephrology, The Affiliated Hospital of Guizhou Medical University, Guiyi Street, Yunyan District, Guiyang 550004, China.  
Department of Endocrinology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China.

Received: 3 February 2022  Accepted: 23 May 2022  
Published online: 30 June 2022

References  
1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. https://doi.org/10.1038/nrendo.2017.151.

2. International Diabetes Federation. IDF Diabetes Atlas - 9th Edition. DiabeteAtlas. http://www.diabetesatlas.org/ (2019).  

3. Thomas MC, Cooper ME, Zimet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81. https://doi.org/10.1038/nrneph.2015.173.

4. Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–77. https://doi.org/10.1038/s41581-018-0001-y.

5. Hsieh JT, Chang FP, Yang AH, Tarng DC, Yang CY. Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach. BMC Nephrol. 2020;21(1):131. https://doi.org/10.1186/s12882-020-01794-w.

6. Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical evidence for best practice. Clin J Am Soc Nephrol. 2016;11(2):354–62. https://doi.org/10.2215/CJN.05750515.

7. Luciano RL, Mocek GW. Update on the Native Kidney Biopsy: Core Curriculum 2019. Am J Kidney Dis. 2019;73(3):404–15. https://doi.org/10.1053/j.ajkd.2018.10.011.

8. Radcliffe NJ, Seehame P, Macsacca SJ, Jerums G, Ekinci EI. Clinical predictors in diabetic kidney disease progression. J Diabetes Investig. 2017;8(1):6–18. https://doi.org/10.1111/jdi.12533.

9. Hogan JJ, Mocanu M, Berns JS. The Native Kidney Biopsy: Update and Evidence for Best Practice. Clin J Am Soc Nephrol. 2016;11(2):354–62. https://doi.org/10.2215/CJN.05750515.

10. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl_1):S1–S13. https://doi.org/10.2337/dc18-S002.

11. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389(10107):1238–52. https://doi.org/10.1016/S0140-6736(16)32064-5.

12. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Rulope L, Zanchetti A, Krummen SE, Kreutz R, Laurent S, Lig G, Mancia R, Narkiewicz K, Ruzicka F, Schmieder RE, Shlyakhto E, Tsoufis C, Aboyans V, Descomps I. Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940.

13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97. https://doi.org/10.1001/jama.285.19.2486.

14. Tervaat TW, Mooymaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Jok K, Noel LH, Radhakrishnan J, Seshan SV, Bajerma IM, Bruint JN, Renal Pathology Society. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–63. https://doi.org/10.1681/ASN.2010010010.

15. Bermejo S, Pascual J, Soler MJ. The current role of renal biopsy in diabetic patients. Minerva Med. 2018;109(2):116–25. https://doi.org/10.23736/ S0026-4806.17.05446-5.

16. Wang J, Han Q, Zhao L, Zhang J, Wang Y, Wu Y, Wang T, Zhang R, Grung P, Xu H, Liu F. Identification of clinical predictors of diabetic nephropathy and non-diabetic renal disease in Chinese patients with type 2 diabetes, with reference to disease course and outcome. Acta Diabetol. 2019;56(8):939–46. https://doi.org/10.1007/s00592-019-01324-7.

17. Dong Z, Wang Y, Qiu Q, Zhang X, Zhang L, Wu J, Wei R, Zhu H, Cai G, Sun X, Chen X. Clinical predictors differentiating non-diabetic renal diseases from diabetic nephropathy in a large population of type 2 diabetes patients. Diabetes Res Clin Pract. 2016;121:112–8. https://doi.org/10. 1016/j.diabris.2016.09.005.

18. Zhou L, Zou G, Li W, Lu J, Ren W. Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus. Eur J Med Res. 2013;18(1):14. https://doi.org/10.1186/2047‑783X‑18‑4.

19. Fiorentino M, Bolognano D, Tesar V, Pisan A, Biesen W, Tripepi G, D’Arrigo G, Gesualdo L, ERA‑EDITA Immunonephrology Working Group. Renal biopsy in patients with diabetes: a pooled meta-analysis of 46 studies. Nephrol Dial Transplant. 2017;32(1):97–110. https://doi.org/10.1093/ndt/gfx679.

20. Liu D, Huang T, Chen X, Xu G, Zhang P, Luo Y, Wang Y, Lu T, Wang L, Xiong M, Geng J, Nie S. The modern spectrum of biopsy‑proven renal disease in Chinese diabetic patients—a retrospective descriptive study. PeerJ. 2018;27(16):e4522. https://doi.org/10.7717/peerj.4522.

21. Zhou XW, Jiang J, Ren W, Fei YY, Peng L, Jiang JL, Lan L, Ye SD. Related factors of diabetic nephropathy in patients with type 1 diabetes mellitus. Zhonghua Yi Xue Za Zhi. 2018;98(30):2403–6. https://doi.org/10.3760/cma.j.issn.0376‑2491.2018.30.007 (Chinese).

22. Wilfred DC, Mysoerek VV, Venkataramana RS, Eshwarappa M, Subramanyan R. Nondiabetic Renal Disease in type 2 Diabetes Mellitus Patients: A Clinicopathological Study. J Lab Physicians. 2015;3(2):94–9. https://doi.org/10.4103/0974‑2727.119850.

23. Zhang J, Wang Y, Li L, Zhang R, Guo R, Li H, Han Q, Teng G, Liu F. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy. Ren Fail. 2018;40(1):243–51. https://doi.org/10.1080/02701220.2018.1456543.

24. Fan JZ, Wang R. Non-diabetic renal disease in patients with type 2 diabetes: a single centre study. Intern Med J. 2018;48(4):451–6. https://doi.org/10.1111/1445‑0191.13708.

25. Bermejo S, González E, López‑Revuelta K, Ibernon M, López‑Martín‑Gómez A, García‑Osuna R, Linares T, Díaz M, Martín N, Barros X, Marzo H, Navarro MI, Esparza N, Elias S, Coloma A, Robles NR, Agraz J, Poch E, Rodas L, Lozano V, Fernández B, Hernández E, Martínez ML, Stanescu RI, Morín RN, Gómez A, Goicoechea M, Calero F, Bonet J, Galceran JM, Liao F, Pascual J, Praga M, Fullaondo X, Soler MJ. Risk factors for non-diabetic renal disease in diabetic patients. Clin Kidney J. 2020;13(3):380–8. https://doi.org/10.1093/ckj/sfx177.

26. Bajema IM, Renal Pathology Society. Pathologic Classification of Diabetic Nephropathy and Non-Diabetic Renal Disease in Patients With Type 2 Diabetes Complicated With Chronic Kidney Disease. Diabetes Metab Syndr Obes. 2019;12(30):1963–72. https://doi.org/10.2147/DMSO.S231444.

27. Xu J, Hu YF, Huang W, Shen PY, Zhang W, Ren H, Li X, Wang WM, Chen N, Pan X. The clinicopathological characteristics of diabetic nephropathy and non-diabetic renal diseases in diabetic patients. Zhonghua Nei Ke
Za Zhi. 2017;56(12):924–9. https://doi.org/10.3760/cma.j.issn.0578-1426.2017.12.007 (Chinese).
30. Fried W. Erythropoietin. Annu Rev Nutr. 1995;15:353–77. https://doi.org/10.1146/annurev.nu.15.070195.002033.
31. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol. 2006;26(4):261–8. https://doi.org/10.1016/j.semnephrol.2006.06.001.
32. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24(3):495–9. https://doi.org/10.2337/diacare.24.3.495.
33. Bhoopalan SV, Huang LJ, Weiss MJ. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Res. 2020;9:F1000 Faculty Rev-1153. https://doi.org/10.12688/f1000research.26648.1.
34. Liu S, Guo Q, Han H, Cui P, Liu X, Miao L, Zou H, Sun G. Clinicopathological characteristics of non-diabetic renal disease in patients with type 2 diabetes mellitus in a northeastern Chinese medical center: a retrospective analysis of 273 cases. Int Urol Nephrol. 2016;48(10):1691–8. https://doi.org/10.1007/s11255-016-1331-y.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.